A b s t r a c t
Aberrant expression of T-cell-associated antigens on Bcell non-Hodgkin lymphomas (NHLs) other than CD43 is a known but uncommonly observed phenomenon. [1] [2] [3] Aberrant expression of CD2, CD3, CD4, CD7, CD8, and CD45RO (UCHL-1) has been reported. 4, 5 Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) is the most cited B-cell malignant neoplasm with aberrant coexpression of T-cell-associated antigens. [6] [7] [8] Other B-cell lymphomas also have displayed this phenomenon. 9 Many of the earlier studies reporting on the dual expression of B-and T-cell antigens by B-cell NHL used anti-B cell and anti-T cell serum assays and/or the demonstration of rosette formation of lymphocytes with sheep RBCs (SRBCs). [10] [11] [12] [13] [14] However, these techniques are rarely used today for that purpose and frequently are fraught with technical problems. 15 Furthermore, rosette formation with SRBCs implicated only CD2 as the T-cell antigen aberrantly expressed on B-cell NHL, and the antiserum assays did not reveal the identification of specific T-cell antigens.
The use of immunofluorescence in subsequent years not only identified the specificity of the aberrantly expressed Tcell antigen but also revealed that rarely more than 1 Tcell-associated antigen can be expressed by a single B-cell lymphoma. 4 Few studies, however, have used multiparameter flow cytometry to characterize these cases, and only rare reports describe such cases in any substantial detail. 16, 17 The obvious questions relating to the incidence, biology, and clinical behavior of such lymphomas remain to be answered. We studied the clinicopathologic details of these rare cases to identify any unusual clinical behavior and facilitate understanding of the biology of these neoplasms.
Flow Cytometric Evaluation
Fresh tissues were transported immediately in RPMI solution to the flow cytometry laboratory. Lymphocytes were disaggregated and released from solid tissue by RPMI injection. Cells were stained with various combinations of the following fluorescein isothiocyanate-or phycoerythrinlabeled monoclonal antibodies against the following antigens: CD1, CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD19, CD20, CD23, HLA-DR, IgG, IgM, IgD, IgA heavy chains, and kappa and lambda light chains. In selected cases, monoclonal antibodies against other antigens also were run, including CD13, CD14, CD33, CD34, CD41a, and terminal deoxynucleotidyl transferase. Two-color flow cytometric immunophenotyping was performed on a FACScan (Becton-Dickinson, San Jose, CA) or a Coulter XL cytometer (Coulter, Miami, FL) by collecting 10,000 ungated list mode events, selecting an appropriate lymphocyte gate on the combination of forward and side scatter, and analyzing cells with the most appropriate lymphocyte gate. In the cases of more than one lymphocyte gate, the gate with the largest number of B cells and/or showing aberrant coexpression of antigens and closely corresponding to the cell size of the lymphoma in question was chosen for analysis. However, with few exceptions, similar data were obtained from additional gates when present.
An antigen was considered positively expressed when at least 25% of the gated lymphocytes expressed that antigen. Clonality was determined when the immunoglobulin kappa light chain/lambda light chain ratio was more than 4:1 or less than 1:2 in a substantial population of B lymphocytes. 18 Only cases with unequivocal aberrant expression of the T-cell-associated antigens (other than CD5) were included. This definition of "unequivocal aberrant expression" included the following: (1) cases in which aberrant expression was demonstrated by dual expression of the B-cell antigens (CD19 and/or CD20) and T-cell-associated antigens (2 cases); (2) cases in which expression of 1 T-cell antigen was grossly (>50 percentage points or more) in excess of CD3 expression (7 cases). CD3 was chosen as the reference T-cell antigen because of its specificity for T cells, and in none of our cases was CD3 aberrantly coexpressed on CD20+ B lymphocytes. This strict definition was chosen to exclude the possibility of contamination by monocytes or macrophages that normally express CD2 and CD4 antigens and may lead to slightly excessive readings for CD2 and/or CD4 antigens. None of the 9 cases showed unusual morphologic features. CD2 was the most common aberrantly expressed Tcell-associated antigen seen in 2 cases of CLL/SLL ❚Figure 1❚ and ❚Image 1❚, 2 cases of follicle center cell lymphoma (FCCL) ❚Figure 2❚ and ❚Figure 3❚, and 1 case of diffuse large B-cell lymphoma. Viciana et al 8 described 1 case of CLL with CD2 expression that showed unusually aggressive clinical behavior. We did not observe, however, unusually aggressive behavior in cases 2 and 3, which were Rai stages II and I, respectively. Similarly, a report 19 of CD8+ CLL/SLL describes unusual disease progression, but no unusual disease progression was noted in our cases 1 and 4 or in cases in several other reports 6, 7, 17, 20, 21 ❚Table 3❚ ❚Figure 4❚. Both patients with CD2+ FCCL had advanced stage disease; however, this cannot be attributed unequivocally to aberrant CD2 expression in the absence of statistical comparisons. One of the two cases of FCCL showed nodular and diffuse morphologic features with small and large cleaved and noncleaved cells and, thus, did not have low-grade morphologic features ❚Image 2❚.
Results

Nine
Discussion
We have described 9 well-characterized cases of Bcell NHLs that showed aberrant coexpression of 1 or 2 © American Society of Clinical Pathologists T-cell-associated antigens. This phenomenon has been reported previously but only rarely documented with adequate clinicopathologic details. Most of the reported cases implicated CLL as the most common B-cell malignant neoplasm with aberrant expression of T-cell-associated antigens. It is unclear, however, whether this reflects the sheer number of CLL cases identified and analyzed or whether this phenomenon is truly more common with CLL.
We found CD2 as the most common aberrantly expressed T-cell-associated antigen. CD2 is a transmembrane glycoprotein that is implicated in signal transduction and serves as a receptor for various ligands, mainly CD58, but also CD48, CD59, and CD15. The CD2 molecule, also known as SRBC receptor, is responsible for rosette formation of T lymphocytes with SRBC and, as such, has been used widely to identify T cells in earlier studies. [12] [13] [14] Most thymocytes, including double negative (CD4-CD8-), double positive (CD4+CD8+), and single positive (CD4+CD8-or CD4-CD8+) cells; peripheral CD4+ and CD8+ T cells; and NK cells, express CD2 receptor. 22 Earlier studies also revealed that a small proportion of mature surface immunoglobulin-expressing B cells express CD2, as indicated by rosette formation with SRBC and a positive reaction with anti-T-cell serum. 23, 24 The fact that CD2 is expressed The expression of CD8, both on the cell surface and in soluble form in the serum of patients with B-cell NHL, is likely the next most common aberrantly expressed Tcell-associated antigen after CD2. [25] [26] [27] Although CLL is the most cited B-cell malignant neoplasm, rare cases of mantle cell lymphomas with aberrant expression of CD8 also are described. 16 CD8 is a 2-chain cell surface glycoprotein that is expressed on a subset of thymocytes, NK cells, and peripheral T cells and functions as a coreceptor molecule that binds with a major histocompatibility complex class I molecule and, as such, is involved in T-cell receptor ligand binding and T-cell activation. 28 Because of more than occasional identification of CD8+ B-CLL, it can be speculated that these lymphomas may represent clonal expansion of an as yet unidentified subset of normal B lymphocytes that express CD8 or, alternatively, genetic aberrations that are unique to the pathogenesis of some B-CLL that may lead to activation of the CD8 receptor gene in some cases. The latter hypothesis is supported by the demonstration of anomalous configuration of the CD8alpha gene owing to alterations in the cisacting regulatory elements upstream of the coding sequence in a case of CD8+ B-CLL expressing only CD8 alpha/alpha homodimers. 17 In contrast with a few reports, 4,5 we did not identify unequivocal aberrant expression of CD3 in any of our B-cell lymphoma cases.
The expression of CD5 by CLL and mantle cell lymphoma does not constitute aberrant expression, because these malignant neoplasms are thought to represent clonal expansion of a CD5+ subpopulation of B lymphocytes that ❚Image 1❚ (Case 3) Chronic lymphocytic leukemia/small lymphocytic lymphoma in a node showing numerous proliferation centers/pseudofollicles (A) and composed of small lymphocytes with round nuclei (B) (A, H&E, ·20; B, H&E, ·400).
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normally is present in the mantle zone cells of secondary follicles. 29 A few cases of diffuse large B-cell lymphoma also express CD5 that might result from large cell transformation of a CD5+ subpopulation of small B lymphocytes.
The expression of CD7 by mantle cell lymphoma is previously unreported ❚Image 3❚. Although CD7 frequently is identified in cases of minimally differentiated acute myelogenous leukemia (AML-M0 in the French-American- British classification), its expression in mature B-cell lymphomas is rare.
The expression of both CD4 and CD7 by a diffuse large B-cell lymphoma in our series is quite intriguing and the least understood. The CD4 coreceptor normally is present on a subset of thymocytes, peripheral T cells, and monocytes or macrophages, whereas CD7 is present on all T lymphocytes, NK cells, and pluripotent hematopoietic stem cells. However, unlike CD2 and CD5, no B-cell fractions are known to express CD4 and CD7 normally. One plausible explanation is the deregulated control of gene expression in malignant B cells, which leads to activation of some silent or repressed genes of T-cell differentiation.
It has been shown that the PAX5-negative pro-B cells that express the genes associated with B-cell differentiation (E2A, EBF, VpreB, lambda5, Igalpha, and Igbeta) can be directed to T-cell differentiation on appropriate stimulation. 30, 31 However, in the presence of PAX5, pro B-cells differentiated only along B-cell lineage, leading to the hypothesis that the transcription factor PAX5 has a dual function in B-lineage commitment by activating B-lymphoid genes and simultaneously repressing lineage-inappropriate genes. It can, therefore, be speculated that deregulation or inactivation of PAX5 in malignant B cells leads to unopposed activation of certain lineage-inappropriate genes. Consistent with the hypothesis of inappropriate activation of T-cell-associated antigens was the finding of appearance of CD8 in long-term cultures of B-CLL cells. 32 Formal proof of this hypothesis is yet to be provided, however.
The expression of T-cell-associated antigens in B-cell NHL has diagnostic and pathogenetic significance. Normal B cells do not express T-cell-associated antigens in substantial amounts. This observation was verified in our group of No proliferation centers or pseudofollicles were present, and prolymphocytes or immunoblasts were not identified (A, H&E, ·100; B, H&E, ·400).
